PURPOSE The population of Chile has aged, and in 2017, cancer became the leading cause of death. Since 2005, a national health program has expanded coverage of drugs for 13 types of cancer and related palliative care. We describe the trends in public and private oncology drug expenditures in Chile and consider how increasing expenditures might be addressed.
INTRODUCTION
As life expectancy in Chile has reached 77 years for men and 83 years for women, cancer prevalence and mortality have increased. [1] [2] [3] The cancer mortality rate was estimated to be approximately 156 per 100,000 in 2018, approaching the higher rates of 164 in upper-middleincome countries and 230 in high-income countries. 4 For more than 2 decades, cancer was the second leading cause of death after cardiovascular disease, but overtook cardiovascular disease in 2017, growing at a rate of 31.2 per 100,000 from 1997 to 2017, faster than upperincome and upper-middle-income countries. 5 The highest rates of cancer mortality for men are for stomach (26.0 per 100,000), prostate (25.2 per 100,000), and lung (22.8 per 100,000) cancer, and among women, breast (18.4 per 100,000), colorectal (17.3 per 100,000), and stomach (12.4 per 100,000) cancer. Cancer mortality in the age group under 15 years is estimated at 3.3 per 100,000, led by leukemia (1.6 per 100,000). 4 In 2014, pharmaceutical expenditures in Chile totaled US$3.9 billion, which represented approximately 1.5% of gross domestic product, or 19.2% of total health expenditures. 6 This proportion was above the Organisation for Economic Co-Operation and Development countries' average of 1.4% and 15.9%, respectively. 7 Public and private insurance covered approximately 40%-60% of total pharmaceutical expenditures. The remaining drugs were sold in private pharmacies and paid out of pocket (OOP). 6 In 2015, 32.2% of total health expenditures were paid OOP, and 30%-32% of total OOP spending was devoted to pharmaceuticals. [8] [9] [10] Public and private spending on cancer drugs in Chile has not been studied.
The Health System and Oncology Drugs
Approximately 75% of the population is covered by the Fondo Nacional de Salud (FONASA), 18% by private health insurance (Instituciones de Salud Previsional [ISAPREs]), 3% by the Ministry of Defense, and the remaining by other programs. 11 In 2005, a mandatory program, AUGE (Universal Access with Explicit Guarantees), was initiated to address noncommunicable diseases and injuries. 12 Since then, AUGE has expanded and as of 2018, covers 80 health conditions and interventions, including 13 types of cancer and associated palliative care (Table 1 ). There are guiding protocols for each cancer type, including a list of recommended drugs that should be available in public and private facilities (Appendix Table A1 ). 13 In 2016, a public fund (Ricate Soto) was created to subsidize high-cost pharmaceuticals, including trastuzumab, a treatment of breast cancer. 14 Under both programs, drugs are provided free of charge in the public system, whereas patients with private insurance pay a 20% copayment.
Regulatory Framework
Drugs used for cancer treatment can be categorized into originator branded and generics (including branded generics). Unbranded generics are marketed using the name of the active ingredient, whereas branded generics use a name other than the active ingredient. Originatorbranded drugs are often protected by either patents or data exclusivities. Patents allow their holders to exclude others from manufacturing or selling the product covered by the patent for 20 years from the date of patent filing, whereas data exclusivity provides rights to originator companies for 5 years after new drug approval. 15 In Chile, the prices of originator-branded drugs are among the highest in Latin America, whereas the prices of generics are among the lowest. 16 The price difference between unbranded generics and originator-branded drugs is approximately 10-to 15-fold. 16, 17 Measured by volume, generics account for 47% of the Chilean market, but if branded generics are included, this figure increases to 88%. 16 One important costcontainment policy is to promote generic substitution after the patents on originator-branded medicines expire. 18 In 2008, a bioequivalence program was launched that required generic manufacturers to demonstrate equivalence with the original drug. The program has been gradually implemented. 19, 20 
Objectives
We analyzed trends in public and private spending on oncology drugs in Chile from 2012-2017. To our knowledge, this article is the first to aggregate such expenditures.
Specifically, we aimed to:
• Estimate the size, mix, and growth of oncology drug expenditures; • Identify the main sources of funding for oncology drugs;
• Analyze factors that contributed to the growth of oncologic drug expenditures, namely price, use, and the introduction of new drugs;
CONTEXT

Key Objective
To examine spending on oncology drugs in Chile, a transitioning upper-middle-income country in which cancer recently became the leading cause of death. Knowledge Generated From 2012-2017, expenditures on oncology drugs increased by an annualized rate of 19.2%, 3 times faster than total health expenditures (6.33%). Seven drugs accounted for half of the total expenditures. Growth was primarily driven by expenditures on originator-branded drugs. Relevance Policies are urgently needed to address the appropriate mix of generic and branded products, including a pathway for accelerating biosimilar approval, and purchasing models based on value. Year Added Type
• Discuss the impact of policies of the Ministry of Health by estimating the share of drug expenditures corresponding to medicines listed versus not listed in the treatment protocols.
METHODOLOGY
Data Sources
We obtained data from the only robust sources available: public sector pharmaceutical data gathered by the national procurement agency Central Nacional de Abastecimiento (CENABAST), 21, 22 and private pharmacies sales data aggregated by IQVIA-Chile. 23, 24 The CENABAST database includes procurement information from all public sector entities, including CENABAST; pharmacies; hospitals, including those of the Armed Forces and universities; health centers; regional health services; and municipalities. We extracted volume and expenditure information from 86,827 transactions of 121 oncology drugs. Table A2 ). We also triangulated with the registry of market authorizations of the Institute of Public Health. 26 The private sales dataset from IQVIA consisted of 302 observations associated with 113 drugs that were sold in private pharmacies from July 2012 to March 2017. The dataset included the following information: chemical and commercial name of the molecule; classification as originator branded, unbranded generic, or branded generic; dosage and number of units; sales revenues; route of administration; manufacturer name; drug class; and prescription versus over-the-counter status. The dataset does not include information on private hospitals and clinics.
Small-molecule or biologic status was determined from the DrugBank, 27 and approval dates were sourced from the CenterWatch Web site (Appendix Table A3 ). 28 
Outcome Variables
Out of each dataset, the following variables were generated: 
Factors Contributing to Growth in Expenditures
We controlled for any seasonality comparing the same quarters from the initial period (Q3, Q4, Q1 of 2012-2013) versus the final period (Q3, Q4, Q1 of 2016-2017).
There was a significant difference in the growth rate by sectors and contributing factors (χ 2 = 197.88; df = 6; P , .0001). More than 90% of the growth in public sector expenditures was driven by an increase in use, with the remaining attributable to price increases. Similarly, in the public off-protocol group, use accounted for most expenditure growth. Approximately 58% of private insurance expenditure growth for on-protocol cancer drugs was associated with price increases. Finally, 45% of the growth of OOP expenditures was driven by use of new medicines (Fig 2) .
Small-Molecule Drugs and Biologics
Of 131 drugs, 108 (82%) were small-molecule drugs, and 23 (18%) were biologics, corresponding to expenditures of US$266 million (66.8%) and US$132 million (33.2%), respectively. Overall, 24 drugs (18.3%) had a corresponding approved generic product, all of which were small-molecule drugs. Twenty drugs (15%) were protected by data exclusivity, including 6 (30%) biologicals.
Expenditures by Brand Versus Generic Products
Originator-branded drugs dominated total spending, accounting for 72% ( Fig 3) . Within the originatorbranded category, public payers accounted for 84% of expenditures. Similarly, public payers accounted for 83% of total sales of generics and branded generics. There was a significant difference in expenditures by sectors and drug products-originator branded, branded generic, and unbranded generic (χ 2 = 70.68; df = 6; P , .0001). For example, the share of expenditures on originatorbranded-on-protocol drugs in the public sector reached 80.8% versus 65.5% in private insurance plans. For offprotocol drugs, the percentage of originator-branded drugs was 55.6% in the public sector and 77.4% for medications purchased OOP.
Top 7 Drugs
Public and private spending on cancer medicines was heavily concentrated, with 7 drugs accounting for 50% of total public and private expenditures. Of 131 oncologic drugs, the top 7 drugs were trastuzumab, rituximab, dasatinib, imatinib, triptorelin, nilotinib, and methotrexate (Fig 4) . These drugs were used for the treatment of leukemia, non-Hodgkin lymphoma, bone, prostate, and breast cancers. Of the top 7, all except triptorelin (a prostate cancer treatment) were part of the official protocols. Of the top 7, 2 were biologicals, and 3 had patents in Chile: trastuzumab (patent issued: 2018); imatinib (patent issued: 2014); and nilotinib (patent issued: 2008). None of the 7 had data exclusivity. 
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DISCUSSION
Because cancer became the leading cause of death around 2017, our data show that the government allocated significant resources to oncology drugs. During the study period, total expenditures on such drugs increased by 120%, or an annualized rate of 19.2%, 3 times the growth rate of total health expenditures (6.33% per year). Growth in public sector spending on oncology drugs was slightly higher, at 136%, or 21% annualized, more than 3 times the growth rate of the public health budget (6.53% per year). Annual growth in public spending on oncology drugs in Chile was much higher than worldwide annual spending growth on oncology drugs (21.0% v 11.8%). 34 Drug expenditure per capita was US$197 in 2017, compared with US$439 in the worldwide reference group. 35 Although Chile is transitioning to a high-income economy, 36 a continuous trend of increased spending on cancer drugs may be fiscally unsustainable.
Increased volume associated with expanded coverage rather than price increases was the driving force underlying increased spending in the public sector, accounting for approximately 94% of such growth. In contrast, increasing prices accounted for 58% of expenditure growth in onprotocol drugs for private insurers. These results suggest that the public sector has been more successful in containing price increases than the private insurance sector, especially for on-protocol drugs.
One possible explanation for this difference is market power. Although Chile has no drug price control policy, the government is a large buyer and uses the well-established e-platform, ChileCompra, 22 to attract many bidders for offpatent drugs and thereby obtain better prices. 22 In contrast, the private insurance sector consists of smaller players reimbursing prescriptions provided through pharmacies, decreasing their bargaining leverage.
In general, the health system has little means to ensure that the 50 on-protocol drugs are used only for the patient subgroups or the disease stage indicated in the protocols for whom these drugs are likely to be most effective.
For example, methotrexate is indicated for acute leukemia but is also used for osteosarcoma, breast cancer, and Hodgkin lymphoma, where benefits are more uncertain. 37 Trastuzumab is recommended for a limited number of breast cancer types but can be used more broadly. 38 on-protocol cancer drug expenditures. Among the top 7 drugs, originator-branded products accounted for 83.8% of expenditures, due in part to patent protection. However, there is still room for improvement in the public on-protocol sector; excluding drugs under patent and data protection, originator-branded products account for approximately 28% of volume despite the availability of generics or branded generics.
Off-protocol expenditures have been growing faster than on-protocol expenditures in the public sector, at 156% versus 127%, respectively ( Fig 2) . Although off-protocol drugs represent approximately 9% of the total volume in the public sector, they represent approximately 30% of total public expenditures. The public health system has limited influence over the choice between generic or nongeneric prescribing, and more expensive brandedoriginal drugs can be used, according to clinician preference, suggesting that some clinicians and health managers prefer newer, not widely used, and more expensive originator-branded drugs, the additional therapeutic value of which is uncertain. Similarly, hospitals and other health facilities have procurement autonomy, even for on-protocol drugs. 22 If we exclude drugs under patent and data protection, 30% of the volume of off-protocol drugs in the public sector are originator-branded products (Fig 4) . Most generics and branded generics continue to lack bioequivalence proof, potentially discouraging generic use (Appendix Table A3 ). 42, 43 This study has limitations; data from private hospitals and clinics were not available, and these sources are estimated to account for approximately 20% of total drug expenditures. 6 The datasets did not allow differentiation of oncology from nononcology uses of medications that have multiple indications. For example, rituximab could contribute significantly to expenditures for rheumatoid arthritis, but this is unlikely to change its place in the top 7 drugs. Our findings may also be sensitive to study design choices: we excluded certain adjunct palliative medications but included others with alternate uses, such as dexamethasone.
We were unable to compare unit drug prices because public and private volume was reported in different units, but we were able to do so in within-sector comparisons.
In conclusion, total oncology drug expenditures were driven by public sector spending, helping to ensure access for 14.1 million Chileans. However, the rate of growth of oncology drugs was more than 3 times public health expenditure growth, indicating that this trend may be fiscally unsustainable. The Ministry of Health protocols are intended to optimize patient care while maintaining fiscal prudence-approximately 70% of total public oncology expenditures were for on-protocol drugs. However, originalbranded drugs dominate the top 7 drugs that account for 50% of total expenditures, including 3 patent-protected drugs. Off-protocol use of newer drugs is expanding. Because cancer is now the leading cause of death, serious consideration should be given to the appropriate mix of on-versus off-protocol drugs, generic versus branded drugs, and the curbing of prescriptions; also, in circumstances in which benefit remains uncertain, by exploring models of purchasing based on value. Abbreviation: FDA, Food and Drug Administration.
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